nD QSAR: A medicinal chemist's point of view

Quantitative Structure-Activity Relationships

Volumn 21, Issue 4, 2002, Pages 391-396

  Müller, Gerhard ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; BATIMASTAT; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; METALLOPROTEINASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEINASE INHIBITOR; RITONAVIR; ROSIGLITAZONE;

CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; DRUG CONFORMATION; DRUG INDUSTRY; DRUG RESEARCH; LIGAND BINDING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 0036798637     PISSN: 09318771     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-3838(200210)21:4<391::AID-QSAR391>3.0.CO;2-L     Document Type: Review

References (22)

1. Drews, J., Drug discovery: A historical perspective, Science 287, 1960-1963 (2000).
2. Drews, J., In Quest of Tomorrow's Medicines, Springer Verlag, New York 1998.
3. Drews, J., Drug Discovery today - and tomorrow, Drug Discov. Today 5, 2-4 (2000).
4. Dolle, R. E., Comprehensive Survey of Combinatorial Library Synthesis: 2000, J. Comb. Chem. 3, 477-517 (2001).
5. Collins, F. S., Patrinos, A., Jordan, E., Chakravarti, A., Gesteland, R., and Walters, L., New goals for the U.S. human genome project:1998-2003, Science 282, 682-689 (1998).
6. Tollman, P., Guy, P., Altshuler, J., Flanagan, A., and Steiner, M. A Revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry, www.bcg.com/publications/files/eng_genomicsgenetics_rep_11_01.pdf (2001).
7. Jones, T., Conference talk: Challenges in todays drug discovery, given at the SCI-Meeting Resolving Bottlenecks in Medicinal Chemistry, London (2000).
8. Gurrath, M., Müller, G., and Höltje, H.-D., Pseudoreceptor Modelling in Drug Design: Applications of Yak and PrGen, Perspect. Drug Discov. Des. 12/13/14, 135-157 (1998).
9. Fischer, E., Einfluss der Configuration auf die Wirkung der Enzyme, Ber. Dtsch. Chem. Ges. 27, 2985-2993 (1894).
10. see for example: Shinkai, H., Novel Antidiabetic Agents, Exp. Opin. Ther. Patents 10, 59-66 (2000).
11. Gampe, R. T. Jr, Montana, V. G., Lambert, M. H., Miller, A. B., Bledsoe, R. K., Milburn, M. V., Kliewer, S. A., Willson, T. M., and Xu, H. E., Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors, Mol. Cell 5, 545-555 (2000).
12. see for example: Leung, D., Abbenante, G., and Fairlie, D. P., Protease Inhibitors: Current Status and Future Perspective, J. Med. Chem. 43, 305-341 (2000).
13. Botos, I., Scapozza, L., Zhang, D., Liotta, L. A., and Meyer, E. F., Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding, Proc. Natl. Acad. Sci. USA 93, 2749-2754 (1996).
14. Köck, M., Müller, G., and Kessler, H., Computational Approach to the Receptor-Bound Conformation of Cyclosporin A, Helv. Chim. Acta 77, 171-181 (1994), and references therein.
15. Sharff, A. J., Rodseth, L. E., Spurlino, J. C., and Quiocho, F. A., Crystallographic evidence of a large ligand-induced hinge-twist motion between the two domains of the maltodextrin binding protein involved in active transport and chemotaxis, Biochemistry 31, 10657-10663 (1992).
16. Vyas, N. K., Vyas, M. N., and Quiocho, F. A., Comparison of the periplasmic receptors for L-arabinose, D-glucose/D-galactose, and D-ribose. Structural and Functional Similarity, J. Biol. Chem. 266, 5226-5237 (1991).
17. Sack, J. S., Saper, M. A., and Quiocho, F. A., Periplasmic binding protein structure and function. Refined X-ray structures of the leucine/isoleucine/valine-binding protein and its complex with leucine, J. Mol. Biol. 206, 171-191 (1989).
18. see for example: Clark, D. E., and Pickett, S. D., Computational methods for prediction of "drug-likeness", Drug Discov. Today 5, 49-58 (2000).
19. Sinko, P. J., Drug Selection in early drug development: Screening for acceptable pharmacokinetics properties using combined in vitro and computational approaches, Curr. Opin. Drug Discov. Dev. 2, 42-48 (1999)
20. Netzer, R., Ebneth, A., Bischoff, U., and Pongs, O., Screening lead compounds for QT interval prolongation, Drug Discov. Today 6, 78-84 (2001).
21. see for example: Wess, G., Urmann, M., and Sickenberger, B., Medicinal Chemistry: Challenges and Opportunities, Angew. Chem. Int. Ed. 40, 3341-3350 (2001).
22. Jacoby, E., A novel chemogenomics knowledge-based ligand design strategy-application to G protein-coupled receptors, Quant. Struct.-Act. Relat. 20, 115-123 (2001).